Evaluating and mitigating fracture risk in established rheumatoid arthritis

被引：24

作者：

Mullen, Matthew B. ^{[1
]}

Saag, Kenneth G. ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL 35294 USA

来源：

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2015年 / 29卷 / 4-5期

关键词：

Fracture risk; Rheumatoid arthritis; Osteoporosis; Glucocorticoid-induced osteoporosis; BONE-MINERAL DENSITY; MODIFYING ANTIRHEUMATIC DRUGS; LOW-DOSE METHOTREXATE; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; DOUBLE-BLIND; VITAMIN-D; BIOCHEMICAL MARKERS; TURNOVER MARKERS; ZOLEDRONIC ACID;

D O I：

10.1016/j.berh.2015.09.005

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Patients with rheumatoid arthritis are predisposed to systemic bone loss, and they are at an increased risk of fractures. Although there are similarities in the patient demographics between rheumatoid arthritis patients and the general population of osteoporosis patients, there are factors, particularly the use of glucocorticoids, which are specific to rheumatoid arthritis. These factors can lead to an increased risk of bone loss and fracture. Given that fractures are often very debilitating, especially in elderly patients, it is of paramount importance for the practicing rheumatologist to be aware of ways to reduce the risk of fracture in patients with rheumatoid arthritis. This review discusses currently available modalities for fracture risk assessment as well as pharmacologic and lifestyle interventions available to treat and prevent bone loss in rheumatoid arthritis patients. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：614 / 627

页数：14

共 88 条

[1]

Adachi JD, 2001, ARTHRITIS RHEUM-US, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO

[2]

2-W

[3]

BIJLSMA JWJ, 1988, BRIT J RHEUMATOL, V27, P215

[4]

Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures [J].

Black, DM ;

Arden, NK ;

Palermo, L ;

Pearson, J ;

Cummings, SR .

JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (05) :821-828

[5]

BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI [DOI 10.1056/NEJMOA067312, 10.1056/NEJMoa067312]

[6]

Rheumatoid arthritis and falls: the influence of disease activity [J].

Boehler, Christoph ;

Radner, Helga ;

Ernst, Michaela ;

Binder, Alexa ;

Stamm, Tanja ;

Aletaha, Daniel ;

Smolen, Josef S. ;

Koeller, Marcus .

RHEUMATOLOGY, 2012, 51 (11) :2051-2057

[7]

Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis [J].

Bolland, Mark J. ;

Grey, Andrew ;

Avenell, Alison ;

Gamble, Greg D. ;

Reid, Ian R. .

BMJ-BRITISH MEDICAL JOURNAL, 2011, 342

[8]

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial [J].

Bone, H. G. ;

Dempster, D. W. ;

Eisman, J. A. ;

Greenspan, S. L. ;

Mcclung, M. R. ;

Nakamura, T. ;

Papapoulos, S. ;

Shih, W. J. ;

Rybak-Feiglin, A. ;

Santora, A. C. ;

Verbruggen, N. ;

Leung, A. T. ;

Lombardi, A. .

OSTEOPOROSIS INTERNATIONAL, 2015, 26 (02) :699-712

[9]

Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density [J].

Bone, Henry G. ;

McClung, Michael R. ;

Roux, Christian ;

Recker, Robert R. ;

Eisman, John A. ;

Verbruggen, Nadia ;

Hustad, Carolyn M. ;

DaSilva, Carolyn ;

Santora, Arthur C. ;

Ince, B. Avery .

JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (05) :937-947

[10]

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis [J].

Boonen, Steven ;

Marin, Fernando ;

Obermayer-Pietsch, Barbara ;

Simoes, Maria E. ;

Barker, Clare ;

Glass, Emmett V. ;

Hadji, Peyman ;

Lyritis, George ;

Oertel, Heide ;

Nickelsen, Thomas ;

McCloskey, Eugene V. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (03) :852-860

← 1 2 3 4 5 6 7 8 9 →